prices don't come down, insurers and employers that insure their employees are going to be caught. Ozempic costs about $900 a month in the U.S., compared to $83 in France and $169 in Japan, countries where regulators set prices. Insurers don't negotiate prices for people to use drugs in unapproved ways. That leaves drugmakers free to set prices as they wish. Most GLP-1 drugs await FDA approval for weight loss, but doctors can still prescribe them for "off label" use. 2 selling nondiscounted drug in the country, after Humira, used for arthritis. Globally, they jumped to $35 billion in sales last year from $9 billion in 2021. Sales of GLP-1 drugs are surging as more and more Americans use them to lose weight. I began to think so after comments made last week by executives at Minnetonka-based UnitedHealth Group, the nation's largest health insurer, about the high prices of drugs known by their class name, GLP-1. This could be the last straw with Big Pharma, drugmakers whose profits are propped up by Americans paying far more than anyone else in the world for prescriptions.ĭemand for weight-loss drugs may be so high - and the tradeoff of long-term improvement in Americans' health so beneficial - that it leads to a fundamental change in drug pricing. The excitement for using diabetes medications to lose weight is having a predictable economic effect - high prices for those drugs.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |